sic to the myocardium also contribute to these control systems. (31) These systems are multilayered and complex, and are ultimately regulated by the parameters that affect cross-bridge cycling within the sarcomere, that precisely organised repeating contractile unit found within all striated muscle, at the molecular level. These include the flow of Ca 2+ through compartments of the cell as well as the interactions between components of the thick and thin filaments of the sarcomere. Upon β-adrenergic stimulation, particular proteins within the cardiomyocyte, including cardiac troponin I and cardiac myosin binding protein C (cMyBPC), undergo orchestrated functional changes that together comprise the positive inotropic and lusitropic effects caused by β-adrenoreceptor activation.
These effects serve to enhance cardiac output: the positive inotropic effect boosts myocyte contractility by optimising Ca 2+ homeostasis, mainly via phosphorylation of Ca 2+ -handling proteins, while the positive lusitropic effect accelerates myocyte relaxation, thereby facilitating an increase in cardiac output via elevation of heart rate. 
structure
Three isoforms of myosin binding protein C, encoded by three distinct genes, viz. fast skeletal (fsMyBPC; ~128 kDa), slow skeletal (ssMyBPC; originally described as MyBPX; ~128 kDa), and cardiac muscle isoforms (cMyBPC; ~137 kDa) have been identified. (8) Myocardial cells were thought to contain only the cardiac isoform throughout development and in adulthood, (12) but ssMyBPC has been shown to be present in moderate amounts in the right atrium and interatrial septum of adult human heart muscle.
Although the three isoforms share a similar structure of immunoglobulin (Ig) and fibronectin type domains, the cardiac isoform has 3 distinguishing structural differences from the skeletal isoforms, viz. an extra Ig domain at the N-terminal (C0), a proline-rich insert in the central C5 domain and three functional phosphorylation sites located in the MyBPC motif, a compact domain located between the N-terminal domains C1 and C2 ( Figure 1 ). (38) These sites have relative sensitivities to the kinases that are present in the cardiac cell, as well as a hierarchy of phosphorylation.
A Ca 2+ /calmodulin-dependent kinase (CamK), which co-purifies with cMyBPC, phosphorylates only the middle site; (8, 60) this step is a prerequisite for protein kinase A (PKA) phosphorylation of the remaining sites upon β-adrenergic stimulation. (11) Since the middle site is phosphorylated by CamK-II, Ca 2+ plays an important role in cMyBPC phosphorylation. McClellan and colleagues (29) speculated that the phosphorylation of this site was possibly constitutive in vivo, as it may be tied to the normal dynamic flux of Ca 2+ in the myocytes.
Dephosphorylation of cMyBPC occurs in response to cholinergic agonists such as acetylcholine. (15) In vitro studies in chicken have
shown that this occurs predominantly via protein phosphatase-2A, (47) which is involved in the dephosphorylation of other sarcomeric proteins and has been shown to co-purify with cMyBPC. (48) It is not known whether there is a specific order for dephosphorylation of cMyBPC.
sArcoMeric ArrANGeMeNt
We have previously proposed that cMyBPC is arranged around the backbone of the thick filament in a "trimeric collar", in which 3 staggered cMyBPC molecules form a ring/collar around the thick filament (Figure 2 ), which is thought to be stabilised by specific interactions that have been demonstrated between domains C5 and C8, and domains C7 and C10, (33) as well as the constitutive interaction between domain C10 and the myosin rod. (39) This model predicts that domains C0C4, forming the Nterminal of MyBPC, has sufficient length to reach out from the thick filament to take part in interactions previously suggested (33) C7 C5 (33) C9 (33) C10 (33) 
C6
Co C1 C4 C5 Actin (24) myosin (17) Actin (52) myosin (9, 61) myosin s2 (13) Titin (10) Lmm (39) to occur with the myosin crossbridge (9, 17, 61) and thin filaments. (24, 43, 52) It is through these interactions, mediated via its N-terminal, that cMyBPC regulates muscle contractility.
iNterActioNs with MyosiN ANd ActiN
Firstly, cMyBPC binds to the S2 region of myosin in a reversible fashion that is dependent on the phosphorylation status of the MyBPC motif. When dephosphorylated, the C1C2 region binds the proximal 126 residues of myosin S2, but upon phosphorylation of the MyBPC motif, the binding is abrogated. (13) Residues within domain C2 (1) and Ser-273/Ser-282 within the MyBPC motif of cMyBPC act synergistically to form an extended myosin S2
"interaction interface". (20) At activating Ca 2+ concentrations, when cMyBPC is fully phosphorylated, increased maximum force has been observed. (29) These results suggest that cMyBPC phosphorylation, regulated by intracellular Ca 2+ levels (to activate CamK-II) and β-adrenergic stimulation (to activate PKA), determines the state of interaction of cMyBPC with myosin S2 and the regulation of cross-bridge cycling, (29) possibly by implementing a tethering-effect on the myosin heads.
However, it is not only via its interaction with myosin S2 that cMyBPC regulates contractility. Early studies have shown that cMyBPC interacted with actin in both regulated and unregulated filaments, (35, 62) producing links between actin and myosin and increasing actin-activated myosin-ATPase activity in vitro. (22, 35, 36) It has been suggested that this interaction involves a region between domains C0 and C1. (24) Furthermore, Razumova and colleagues (43) showed that the C1C2 region of cMyBPC also interacts with actin to affect cross-bridge kinetics (reducing actin filament velocity at high Ca 2+ concentrations), without a requirement for myosin S1 or S2. (50) Interestingly, Herron and colleagues (17) showed that N-terminal fragments of cMyBPC containing the pro-ala-rich linker sequence between C0 and C1 was able to switch on the thin filament by a mechanism different from that of Ca 2+ . The precise mechanism for this Ca 2+ -independent activating effect of N-terminal cMyBPC on force production and crossbridge cycling remains to be established.
Thus, N-terminal domains of cMyBPC interact with both thick and thin filaments and can therefore modulate actomyosin contacts through these interactions directly. (50) It has been suggested that cMyBPC could give rise to an internal load by tethering myosin S2 to the thick filament, thereby limiting myosin head position and/ or mobility, and limiting cross-bridge formation, (33) or via its interaction with the thin filament when cMyBPC is phosphorylated. (23) Such an internal load would serve a useful function if cMyBPC stores some of the energy generated during systole to assist in the filling of the heart during diastole. (23) The effect of cMyBPC to slow cross-bridge formation may appear to be deleterious to contractile function; however slowed rates of cross-bridge cycling may be beneficial in vivo by prolonging systolic ejection and increasing contractile efficiency by minimising ATP utilisation, as well as promoting diastolic filling rates. (24) Removal of the constraint either by MyBPC deficiency, such as occurs in some forms of cardiomyopathy, or its phosphorylation under adrenergic stimulation, would bring the myosin head in
CArdiAC myosin BindinG ProTEin C FiGure 2: Based on protein interaction studies, we have proposed a trimeric collar model to explain the arrangement of cmyBPC within the thick filament of the sarcomere. in this model, three cmyBPC molecules form a belt or collar around the thick filament (shown as a yellow rod), with domains C5-C7 of one molecule interacting with domains C8-C10 of the next in an overlapping, parallel arrangement. (33) in this model, we also propose that the n-terminal domains (C0-C4) extend into the interfilament space between thick filaments, where the cmyBPC motif would be available to interact with the region of myosin that supports the myosin head, viz. the myosin s2 region (myosin and additional thick filaments not shown). [image taken from moolman-smook (33) ]
closer proximity to actin, thereby enhancing the probability of cross-bridge formation and increasing power output, (16) contractility, (42) and V max , (18) as well as lowering viscous load. (42) FuNctioN oF cMybPc
Thick filament formation
In vitro evidence suggests that cMyBPC plays an important role in the formation of myofibrils in skeletal and cardiac muscle. (8) Purified myosin can self-assemble into thick filaments in the absence of cMyBPC; however, only in the presence of the normal content of cMyBPC do synthetic thick filaments resemble native thick filaments in their thickness, length, bare-zone and distribution of myosin heads. (8, 19, 28, 49) However, while in vitro experiments indicated that cMyBPC may play a role in thick filament formation, murine knockout models of cMyBPC did not show a lack of sarcomere formation. (14, 30) Rather, transgenic mice with no cMyBPC expression are viable and have regular sarcomere striations such as the Z-line, A-band and M-line, but these sarcomeric features are frequently misaligned. (14) Thick filament stability
Moreover, evidence suggests that cMyBPC phosphorylation provides thick filament stability (25) showed that cMyBPC exists in 2 different forms that produced either stable or unstable thick filaments. (25) The stable form had well-ordered myosin heads and required cMyBPC phosphorylation, while the unstable form was associated with disordered myosin heads and unphosphorylated cMyBPC. Unphosphorylated cMyBPC was more easily proteolysed even within intact cardiac cells, causing cMyBPC and myosin to be released, and myofilaments deficient in cMyBPC were fragmented by shear force that is well tolerated by the stable form. (25) cmyBPC and cardiac function
While the presence of cMyBPC is not absolutely required for sarcomere formation, the lack of cMyBPC (14, 40, 54, 55, 56) and decreased levels of cMyBPC phosphorylation (45) in the myocardium have been implicated in both systolic and diastolic dysfunction.
Further animal studies showed that homozygous and heterozygous cMyBPC-null mice exhibited different cardiac disorders. 
In addition, Palmer and colleagues (41) showed that cMyBPC appeared less important for initiating force development than for sustaining force and muscle stiffening so that systole can extend normally throughout ejection. Without it, chambers are capable of only a very short eject period: time to peak elastance is reduced, with premature relaxation starting shortly after ejection and resulting in reduced cardiac output. This reduced elastance appeared to be fairly specific to cMyBPC-deficient hearts, as it was not mimicked in other models of cardiac dysfunction such as autoimmune myocarditis and myocardial stunning. These findings (40, 41) suggested that cMyBPC provided mechanical stability to the myofilament lattice in such a manner as to significantly influence the transmission of force across the sarcomere and sustain systolic stiffening.
In a long-term follow-up study of transgenic mice expressing truncated cMyBPC that lacked C-terminal domains, cardiac hypertrophy was observed in adults older than one year. (65) When these were stressed either by physical exercise or chronic β-adrenergic stimulation, bradycardia and sudden death was observed, while unstressed transgenic animals had a normal life span. This suggests that the unstressed heart was able to compensate effectively for the intrinsic mechanical and kinetic deficits resulting from cMyBPC defects, but that functional deficits presented at the whole organ level upon exposure to stress. These findings are similar to what has been observed in human subjects, where mutations in the cMyBPC-encoding gene, MYBPC3, are often, but not always, associated with late onset and benign phenotype. (65) Phosphorylation patterns of cMyBPC have also been shown to have a significant effect on the whole-heart function and cardiac haemodynamics. (45) In various mouse models of cardiac stress, cMyBPC was extensively phosphorylated under basal conditions and became dephosphorylated during the development of heart failure or pathological hypertrophy, with the trisphosphorylated form largely or completely absent in the advanced stages of heart failure. (45) This phenomenon appeared to be independent of the type of cardiac stress, as pressure overload, ischaemic-reperfusion injury, and various genetic alterations in the cardiac machinery all resulted in significantly decreased phosphorylation. In mice engineered to express a non-phosphorylatable form of cMyBPC, hearts-appeared overtly normal with no cardiac hypertrophy and/or dilation. However, sarcomeric patterns were ill-defined with altered H-zones and M-lines, and genes associated with a hypertrophic response (such as atrial-natriuretic factor, β-MHC, brain natriuretic peptide, and skeletal β-actin) were up-regulated.
Moreover, contraction and relaxation were significantly decreased, indicating that the capacity for cMyBPC phosphorylation is essential for normal cardiac function. (45) Reduced cMyBPC phosphorylation has been reported in human atrial fibrillation (6) and in failing human hearts, (7) which forms part of the picture of attenuated β-adrenergic responsiveness (desensitisation) during heart failure.
This may be mainly as a result of decreased β1-adrenoreceptor number and function and thus attenuated PKA activity (27, 57) but likely contributes to the downwards spiral of contractile dysfunction.
While dephosphorylated cMyBPC may be associated with disease either as cause or consequence, cMyBPC phosphorylation can actually protect the myocardium from ischaemic injury: the hearts of transgenic mice engineered to express a constitutively phosphorylated form of cMyBPC were resistant to ischaemia-reperfusion injury. (46) Taken together, these studies show that, while cMyBPC is not absolutely essential for sarcomere formation, it is necessary for the integrity of sarcomere structure and its phosphorylation in response to adrenergic stimulation is crucial for normal systolic and diastolic cardiac function.
PAthoPhysioloGicAl MechANisM oF cMybPc deFects
The mechanism by which mutant cMyBPC protein causes dysfunction, either via haploinsufficiency (too little protein) or "poison" peptide (a dysfunctional protein), has also been investigated, but have yielded contradictory results (64) showed that mutant cMyBPC (lacking only the C-terminal myosin-binding domain C10) was stably expressed and, although it was incorporated into the sarcomere, it was not restricted to its normal position within the A-band, while mutant cMyBPC protein lacking both the myosin and titin-binding domains (domains C8 through C10) was not detectable. (30, 40, 63) The absence of cMyBPC protein in some of these models precludes the possibility that the truncated MyBPC always acts as a "poison" peptide and the cardiomyopathy observed must therefore be due to the mechanical consequences of the absence or insufficient levels of cMyBPC. (40) What may these mechanical consequences be? It has been shown that structural changes occur in the thick filament upon cMyBPC phosphorylation, with different degrees of cMyBPC phosphorylation resulting in distinct changes in the appearance of isolated thick filaments. In the absence of cMyBPC phosphorylation, the thick filament had a disordered structure (myosin heads extending at different angles from the backbone). The addition of the first phosphate to cMyBPC induced a change from the disordered structure to a tight structure (myosin heads lying along the backbone). With the addition of the second and third phosphates, by PKA, greater order of myosin heads and looser packing of myosin, concomitant increase in thick filament diameter in the region of the sarcomere which houses cMyBPC, was observed. (26, 59) In the fully phosphorylated state, the myosin heads appeared extended from the thick filament backbone, closer to the thin filament surface, favouring interaction between the thick and thin filament. (26) Thus, the packing of myosin filaments and their heads are intimately linked to the state of cMyBPC phosphorylation, where the myosin heads to interact with the thin filament. Phosphorylation of cMyBPC also produces a change in flexibility of the cross-bridges.
It is not yet clear how this occurs, but changes in flexibility of the crossbridges could modulate cross-bridge detachment rate, and changes in the distance from its actin-binding sites as a result of altered packing of myosin rods modulate the attachment rate. (60) Disordering of the arrangement of surface myosin heads and declining contractility are coincident with dephosphorylation of cMyBPC, while rephosphorylation leads to recovery of both crossbridge order and contractility. (26) HCm-causing mutations Figure 4 . Upon PKA-dependent phosphorylation of cMyBPC, the "loose" collar would allow the thick filament to expand and adopt the loose structure which has been associated with increased crossbridge cycling. (26, 29) In support of this hypothesis, we also found, using yeast two-hybrid represented an even more C-terminal region, encompassing midway through domain C8 through to domain C10, while P213 was intermediate in size, encoding region C7 through C10. Co-immunoprecipitation experiments using these N-and C-terminal fragments of cMyBPC showed that the trisphosphorylated bait C1P 1 P 2 P 3 C2 had a greater affinity for the C-terminal cMyBPC clones C412 and P62 than did the unphosphorylated bait C1C2
( Figure 5 ). These results could be interpreted as follows: when the cMyBPC motif is phosphorylated, the C1 through C2 N-terminal domains make direct contact with C-terminal domains (observed as C1P 1 P 2 P 3 C2 interacting strongly with C412 and P62, Figure 5 ), while, when the cMyBPC motif is unphosphorylated, an interaction between these domains and C-terminal domains is not favoured (observed as weak interactions of C1C2 with C412 and P62, Figure 5 ). Although domain C3 was not part of the constructs used in this assay, the interaction observed between domains C3 and C10 in direct interaction assays by De Lange suggests that interactions of phosphorylated N-terminal domains with C-terminal domains are not perfectly juxtaposed; thus, the This therefore suggests that cMyBPC mutations, both those causing loss of the protein as well as those leading to defective proteins, fit into the same class of pathophysiological mechanism as HCM mutations in other genes that appear to act by increasing the cost CArdiAC myosin BindinG ProTEin C
FiGure 4:
The hypothesised transition of the thick filament from the tight (A) to loose (B) structure upon β-adrenergic stimulation. Under nonstimulated conditions, the myosin rods in the thick filament (shown in yellow) are tightly wound and in this tight structure, three cmyBPC molecules wrap around the thick filament in such a way that domains C5:C8, C6:C9 and C7:C10 of successive cmyBPC molecules interact according to the collar model. Upon β-adrenergic stimulation and trisphosphorylation of the cmyBPC motif, the myosin rods of the thick filament adopts a loose structure with a wider diameter which is proposed to be facilitated by the widening of the cmyBPC collar. Thus, domains C2 or C3 may now interact with domain C10. image A taken from moolman-smook (33) and image B from de Lange.
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of force production, suggesting that an inability to maintain energy homeostasis may underly many, if not all, forms of HCM. (32, 44) In summary, closer investigation of this little understood protein of the sarcomere, driven by its role in HCM, has revealed one of the most potent regulators of cardiac contractility. Phosphorylation of its N-terminus upon adrenergic stimulation, causes increased order in myosin heads as well as increased ATPase activity, F max and Ca 2+ sensitivity of contraction, (38) while its dephosphorylation upon cholinergic stimulation or during low flow ischaemia leads to changes in the sarcomeric thick filament that diminish interaction between myosin heads and actin. This dynamic flux in phosphorylation upon adrenergic stimulation is not only crucial to normal cardiac function and structure, but also vital for protection against ischaemic injury. (46) Genetically-driven deficiency or inadequacy in cMyBPC leads to severe cardiac dysfunction and structural changes, including cardiac hypertrophy and dilation, and particularly attenuates the adaptive increase in left ventricular contractility that follows on B-adrenergic stimulation or pressure overload, (2) resulting in decreased systolic function, and reduced cardiac output. 
